FUJI YAKUHIN CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1930-02-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.fujiyakuhin.co.jp
Study of FYU-981 in Hyperuricemia With or Without Gout
Phase 2
Completed
- Conditions
- Hyperuricemia
- Interventions
- Drug: Placebo, (Oral daily dosing for 8 weeks)Drug: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)Drug: FYU-981 High dose, (Oral daily dosing for 8 weeks)Drug: FYU-981 Low dose, (Oral daily dosing for 8 weeks)
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT02344862
- Locations
- 🇯🇵
Japan, Tokyo, Japan
Clinical Pharmacology of FYU-981 (Elder Subjects)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: FYU-981, (Oral single dosing)
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Fuji Yakuhin Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02344875
- Locations
- 🇯🇵
Japan, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath